MedTrace Logo

A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

NCT03274206 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2020-02-07

No results posted yet for this study

Summary

This study evaluates the efficacy and safety of the experimental drug, BLS-ILB-E710c, in patients with Cervical Intraepithelial Neoplasia 2/3 (CIN2/3). 2/3 of participants will receive the experimental drug, while 1/3 of participants will receive placebo.

Conditions

  • Cervical Intraepithelial Neoplasia Grade 2/3

Interventions

BIOLOGICAL

BLS-ILB-E710c

BLS-ILB-E710c 250mg/capsule

DRUG

Placebo

BLS-ILB-E710c-placebo

Sponsors & Collaborators

  • BioLeaders Corporation

    lead INDUSTRY

Principal Investigators

  • Jae-Kwan Lee, MD, PhD · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-30
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03274206 on ClinicalTrials.gov